Xenetic Biosciences, Inc.
XBIO
$2.45
$0.000.00%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
11/19/2025
-
GuruFocus
11/19/2025
-
ACCESS Newswire
11/14/2025
-
TipRanks Financial Blog
11/13/2025
-
GuruFocus
11/13/2025
-
ACCESS Newswire
Xenetic Biosciences (NASDAQ:XBIO) Announces Quarterly Earnings Results, Beats Estimates By $0.16 EPS
11/13/2025
-
Ticker Report
10/30/2025
-
Zacks Investment Research
10/10/2025
-
GuruFocus
10/10/2025
-
TipRanks Financial Blog
10/10/2025
-
The Fly
10/10/2025
-
TipRanks Financial Blog
10/10/2025
-
The Fly
10/10/2025
-
Seeking Alpha - Healthcare
10/10/2025
-
ACCESS Newswire
10/8/2025
-
MarketBeat
10/8/2025
-
MarketBeat
10/8/2025
-
RTT News - Momentum Stocks
8/13/2025
-
GuruFocus
8/13/2025
-
GuruFocus
8/13/2025
-
ACCESS Newswire
8/13/2025
-
TipRanks Financial Blog
8/12/2025
-
Zacks Investment Research
7/30/2025
-
GuruFocus
7/30/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 16 and 20 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
781 778 7720
Address
945 Concord Street
Framingham, MA 01701
Framingham, MA 01701
Country
Year Founded
--
Business Description
Sector
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company’s proprietary DNase platform is designed to improve...
more